Literature DB >> 26782926

Generation of transgenic cattle expressing human β-defensin 3 as an approach to reducing susceptibility to Mycobacterium bovis infection.

Feng Su1,2, Yongsheng Wang1, Guanghui Liu1, Kun Ru1, Xin Liu1, Yuan Yu1, Jun Liu1, Yongyan Wu1, Fusheng Quan1, Zekun Guo1, Yong Zhang1.   

Abstract

Bovine tuberculosis results from infection with Mycobacterium bovis, a member of the Mycobacterium tuberculosis family. Worldwide, M. bovis infections result in economic losses in the livestock industry; cattle production is especially hard-hit by this disease. Generating M. bovis-resistant cattle may potentially mitigate the impact of this disease by reducing M. bovis infections. In this study, we used transgenic somatic cell nuclear transfer to generate cattle expressing the gene encoding human β-defensin 3 (HBD3), which confers resistance to mycobacteria in vitro. We first generated alveolar epithelial cells expressing HBD3 under the control of the bovine MUC1 promoter, and confirmed that these cells secreted HBD3 and possessed anti-mycobacterial capacity. We then generated and identified transgenic cattle by somatic cell nuclear transfer. The cleavage and blastocyst formation rates of genetically modified embryos provided evidence that monoclonal transgenic bovine fetal fibroblast cells have an integral reprogramming ability that is similar to that of normal cells. Five genetically modified cows were generated, and their anti-mycobacterial capacities were evaluated. Alveolar epithelial cells and macrophages from these cattle expressed higher levels of HBD3 protein compared with non-transgenic cells and possessed effective anti-mycobacterial capacity. These results suggest that the overall risk of M. bovis infection in transgenic cattle is efficiently reduced, and support the development of genetically modified animals as an effective tool to reduce M. bovis infection.
© 2016 Federation of European Biochemical Societies.

Entities:  

Keywords:  HBD3; Mycobacterium bovis; somatic cell nuclear transfer; transgenic cattle; tuberculosis

Mesh:

Substances:

Year:  2016        PMID: 26782926     DOI: 10.1111/febs.13641

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  6 in total

1.  Genome Editing in Large Animals.

Authors:  James West; W Warren Gill
Journal:  J Equine Vet Sci       Date:  2016-03-25       Impact factor: 1.583

2.  Divergent macrophage responses to Mycobacterium bovis among naturally exposed uninfected and infected cattle.

Authors:  Omar A Alcaraz-López; Cindy García-Gil; Claudia Morales-Martínez; Gonzalo López-Rincón; Ciro Estrada-Chávez; José A Gutiérrez-Pabello; Hugo Esquivel-Solís
Journal:  Immunol Cell Biol       Date:  2016-11-11       Impact factor: 5.126

3.  Secretion of IFN-γ by Transgenic Mammary Epithelial Cells in vitro Reduced Mastitis Infection Risk in Goats.

Authors:  Ying Liu; Hongyan Zhang; Shasha Dong; Boyu Li; Weiming Ma; Lijiang Ge; Zhiyong Hu; Feng Su
Journal:  Front Vet Sci       Date:  2022-06-24

4.  Overexpressing ovotransferrin and avian β-defensin-3 improves antimicrobial capacity of chickens and poultry products.

Authors:  Caitlin A Cooper; Mark L Tizard; Tamsyn Stanborough; Sean C Moore; P Scott Chandry; Kristie A Jenkins; Terry G Wise; Terri E O'Neil; Daniel S Layton; Kirsten R Morris; Robert J Moore; Narelle Fegan; Timothy J Doran
Journal:  Transgenic Res       Date:  2018-10-29       Impact factor: 2.788

5.  Expression of recombinant HBD3 protein that reduces Mycobacterial infection capacity.

Authors:  Feng Su; Xin Chen; Xin Liu; Guanghui Liu; Yong Zhang
Journal:  AMB Express       Date:  2018-03-20       Impact factor: 3.298

6.  Efficient Generation of Transgenic Buffalos (Bubalus bubalis) by Nuclear Transfer of Fetal Fibroblasts Expressing Enhanced Green Fluorescent Protein.

Authors:  Fenghua Lu; Chan Luo; Nan Li; Qingyou Liu; Yingming Wei; Haiying Deng; Xiaoli Wang; Xiangping Li; Jianrong Jiang; Yanfei Deng; Deshun Shi
Journal:  Sci Rep       Date:  2018-05-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.